使用一种靶向B细胞成熟抗原的双特异性抗体治疗多发性骨...

icartab

An anti-B cell maturation antigen bispecific antibody for multiple myeloma.

The development of immunotherapies for multiple myeloma is critical to provide new treatment strategies to combat drug resistance. We report a bispecific antibody against B cell maturation antigen (BiFab-BCMA), which potently and specifically redirects T cells to lyse malignant multiple myeloma cells. BiFab-BCMA lysed target BCMA-positive cell lines up to 20-fold more potently than a CS1-targeting bispecific antibody (BiFab-CS1) developed in an analogous fashion. Further, BiFab-BCMA robustly activated T cells in vitro and mediated rapid tumor regression in an orthotopic xenograft model of multiple myeloma. The in vitro and in vivo activities of BiFab-BCMA are comparable to those of anti-BCMA chimeric antigen receptor T cell therapy (CAR-T-BCMA), for which two clinical trials have recently been initiated. A BCMA-targeted bispecific antibody presents a promising treatment option for multiple myeloma.

使用一种靶向B细胞成熟抗原的双特异性抗体治疗多发性骨髓瘤

多发性骨髓瘤的免疫疗法的发展是新的对抗耐药性治疗策略的关键。我们报导了一种靶向B细胞成熟抗原的双特异性抗体（BiFab-BCMA），能强有力地重定向T细胞杀伤恶性多发性骨髓瘤细胞。BiFab-BCMA裂解靶标BCMA阳性细胞的能力是同一种类似的双特异性抗体BiFab-CS1的20多倍。此外，BiFab-BCMA能够在体外强力的活化T细胞并且在多发性骨髓瘤原位移植瘤模型中强烈的介导肿瘤抑制。体内和体外的BiFab-BCMA的活性与CAR-T-BCMA相比，相差无几，这两个临床试验也已经开始了。一个靶向BCMA的双特异性抗体代表着一个对抗多发性骨髓瘤的有前景的治疗方案。

出自爱康得生物技术